Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$310.41
0.600.19%
al cierre: -
$310.00
-0.41-0.13%
After hour: 7:34 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Elevance Health Inc ha un obiettivo di prezzo di consenso pari a $464.62, stabilito in base alle ultime valutazioni degli analisti di 24. Le ultime 3 valutazioni degli analisti sono state rilasciate da Wells Fargo, Baird y JP Morgan il agosto 15, 2025, julio 25, 2025 y julio 22, 2025. Con un obiettivo di prezzo medio di $337 tra le Wells Fargo, Baird y JP Morgan, c'è un implicito 8.71% upside per Elevance Health Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Wells Fargo
Baird
JP Morgan
Barclays
UBS
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Elevance Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/15/2025 | 6.45% | Wells Fargo | $400 → $330 | Maintains | Overweight | |||
07/25/2025 | -4.19% | Baird | $492 → $297 | Maintains | Neutral | |||
07/22/2025 | 23.87% | JP Morgan | $472 → $384 | Maintains | Overweight | |||
07/22/2025 | 5.48% | Barclays | $358 → $327 | Maintains | Overweight | |||
07/21/2025 | — | Argus Research | — | Downgrade | Buy → Hold | |||
07/18/2025 | 40.32% | UBS | $484 → $435 | Maintains | Buy | |||
07/18/2025 | 15.48% | Barclays | $434 → $358 | Maintains | Overweight | |||
07/18/2025 | 16.13% | Guggenheim | $447 → $360 | Maintains | Buy | |||
07/18/2025 | 1.94% | Morgan Stanley | $428 → $316 | Maintains | Overweight | |||
07/18/2025 | — | Leerink Partners | $510 → $310 | Downgrade | Outperform → Market Perform | |||
07/16/2025 | 41.94% | Truist Securities | $500 → $440 | Maintains | Buy | |||
07/15/2025 | 29.03% | Wells Fargo | $478 → $400 | Maintains | Overweight | |||
07/14/2025 | 56.13% | UBS | $555 → $484 | Maintains | Buy | |||
07/09/2025 | 40% | Barclays | $480 → $434 | Maintains | Overweight | |||
06/09/2025 | 61.29% | Truist Securities | $510 → $500 | Maintains | Buy | |||
06/04/2025 | 54.19% | RBC Capital | $478 → $478 | Reiterates | Outperform → Outperform | |||
06/02/2025 | 54.84% | Barclays | $522 → $480 | Maintains | Overweight | |||
04/25/2025 | 50% | Argus Research | $450 → $465 | Maintains | Buy | |||
04/23/2025 | 54.19% | RBC Capital | $478 → $478 | Reiterates | Outperform → Outperform | |||
04/23/2025 | 67.1% | Guggenheim | $518 → $518 | Reiterates | Buy → Buy | |||
04/23/2025 | 56.45% | Cantor Fitzgerald | $485 → $485 | Reiterates | Overweight → Overweight | |||
04/23/2025 | 68.39% | Barclays | $512 → $522 | Maintains | Overweight | |||
04/15/2025 | 70.65% | Baird | $625 → $529 | Downgrade | Outperform → Neutral | |||
04/11/2025 | 64.52% | Truist Securities | $480 → $510 | Maintains | Buy | |||
04/09/2025 | 67.1% | Guggenheim | → $518 | Initiates | → Buy | |||
04/09/2025 | 62.9% | Mizuho | $455 → $505 | Maintains | Outperform | |||
03/17/2025 | 45.16% | Argus Research | → $450 | Upgrade | Hold → Buy | |||
01/29/2025 | 30.77% | Argus Research | $405.4 → $405.4 | Reiterates | Hold → Hold | |||
01/28/2025 | 54.19% | Wells Fargo | $483 → $478 | Maintains | Overweight | |||
01/24/2025 | 56.45% | Cantor Fitzgerald | $485 → $485 | Reiterates | Overweight → Overweight | |||
01/24/2025 | 65.16% | Barclays | $501 → $512 | Maintains | Overweight | |||
01/06/2025 | 54.84% | Truist Securities | $520 → $480 | Maintains | Buy | |||
11/18/2024 | 55.81% | Wells Fargo | $495 → $483 | Maintains | Overweight | |||
11/05/2024 | 62.9% | Mizuho | $585 → $505 | Maintains | Outperform | |||
11/04/2024 | 59.68% | Wells Fargo | $593 → $495 | Maintains | Overweight | |||
10/23/2024 | 77.74% | Morgan Stanley | $643 → $551 | Maintains | Overweight | |||
10/22/2024 | 61.61% | Barclays | $622 → $501 | Maintains | Overweight | |||
10/21/2024 | 56.13% | TD Cowen | $589 → $484 | Maintains | Buy | |||
10/18/2024 | — | Argus Research | — | — | Downgrade | Buy → Hold | ||
10/18/2024 | 79.03% | UBS | $605 → $555 | Maintains | Buy | |||
10/18/2024 | 67.74% | Truist Securities | $620 → $520 | Reiterates | Buy → Buy | |||
10/18/2024 | 54.19% | RBC Capital | $585 → $478 | Maintains | Outperform | |||
10/18/2024 | 56.45% | Cantor Fitzgerald | $600 → $485 | Maintains | Overweight | |||
10/10/2024 | 100.65% | Barclays | $611 → $622 | Maintains | Overweight | |||
10/01/2024 | 93.55% | Cantor Fitzgerald | $600 → $600 | Reiterates | Overweight → Overweight | |||
09/20/2024 | 93.55% | Cantor Fitzgerald | $600 → $600 | Reiterates | Overweight → Overweight | |||
09/10/2024 | 93.55% | Cantor Fitzgerald | $600 → $600 | Reiterates | Overweight → Overweight | |||
09/05/2024 | 98.39% | Stephens & Co. | $615 → $615 | Reiterates | Overweight → Overweight | |||
08/19/2024 | 93.55% | Cantor Fitzgerald | $600 → $600 | Reiterates | Overweight → Overweight | |||
07/23/2024 | 93.55% | Cantor Fitzgerald | $600 → $600 | Reiterates | Overweight → Overweight | |||
07/22/2024 | 91.29% | Wells Fargo | $600 → $593 | Maintains | Overweight | |||
07/19/2024 | 90% | TD Cowen | $624 → $589 | Maintains | Buy | |||
07/18/2024 | 97.1% | Barclays | $621 → $611 | Maintains | Overweight | |||
07/18/2024 | 88.71% | RBC Capital | $575 → $585 | Maintains | Outperform | |||
07/18/2024 | 70.97% | B of A Securities | $646 → $530 | Downgrade | Buy → Neutral | |||
07/15/2024 | 100% | Truist Securities | $600 → $620 | Maintains | Buy | |||
07/10/2024 | 93.55% | Cantor Fitzgerald | $600 → $600 | Reiterates | Overweight → Overweight | |||
06/24/2024 | 107.42% | Morgan Stanley | → $643 | Initiates | → Overweight | |||
06/12/2024 | 93.55% | Cantor Fitzgerald | $600 → $600 | Reiterates | Overweight → Overweight | |||
06/11/2024 | 98.39% | Stephens & Co. | $615 → $615 | Reiterates | Overweight → Overweight | |||
06/04/2024 | 108.39% | B of A Securities | $621 → $646 | Maintains | Buy | |||
05/30/2024 | 103.55% | JP Morgan | $628 → $631 | Maintains | Overweight | |||
05/30/2024 | 109.35% | Baird | → $649 | Initiates | → Outperform | |||
04/24/2024 | 88.71% | Mizuho | $575 → $585 | Maintains | Buy | |||
04/19/2024 | 85.48% | RBC Capital | $574 → $575 | Maintains | Outperform | |||
04/19/2024 | 95.16% | UBS | $585 → $605 | Maintains | Buy | |||
04/19/2024 | 93.55% | Wells Fargo | $557 → $600 | Maintains | Overweight | |||
04/19/2024 | 93.55% | Truist Securities | $580 → $600 | Reiterates | Buy → Buy | |||
04/19/2024 | 94.84% | Jefferies | $602 → $604 | Maintains | Buy | |||
04/19/2024 | 100.32% | Barclays | $584 → $621 | Maintains | Overweight | |||
04/10/2024 | 87.1% | Cantor Fitzgerald | $580 → $580 | Reiterates | Overweight → Overweight | |||
04/08/2024 | 79.68% | Wells Fargo | $561 → $557 | Maintains | Overweight | |||
04/04/2024 | 87.1% | Cantor Fitzgerald | $580 → $580 | Reiterates | Overweight → Overweight | |||
03/06/2024 | 88.39% | Barclays | → $584 | Initiates | → Overweight | |||
02/14/2024 | 87.1% | Cantor Fitzgerald | $547 → $580 | Maintains | Overweight | |||
02/02/2024 | 76.45% | Cantor Fitzgerald | $547 → $547 | Reiterates | Overweight → Overweight | |||
01/25/2024 | 76.45% | Cantor Fitzgerald | $547 → $547 | Reiterates | Overweight → Overweight | |||
01/25/2024 | 85.16% | RBC Capital | $572 → $574 | Maintains | Outperform | |||
01/19/2024 | 76.45% | Cantor Fitzgerald | $547 → $547 | Reiterates | Overweight → Overweight | |||
11/21/2023 | 76.45% | Cantor Fitzgerald | → $547 | Reiterates | Overweight → Overweight | |||
11/17/2023 | 78.06% | JP Morgan | $569 → $552 | Maintains | Overweight | |||
10/19/2023 | 76.45% | Cantor Fitzgerald | → $547 | Reiterates | Overweight → Overweight | |||
10/19/2023 | 89.35% | Morgan Stanley | $585 → $587 | Maintains | Overweight | |||
09/14/2023 | 76.45% | Cantor Fitzgerald | → $547 | Reiterates | Overweight → Overweight | |||
07/25/2023 | 88.71% | Morgan Stanley | $571 → $585 | Maintains | Overweight | |||
07/24/2023 | 88.71% | TD Cowen | $564 → $585 | Maintains | Outperform | |||
07/20/2023 | 84.52% | RBC Capital | → $572 | Reiterates | Outperform → Outperform | |||
07/20/2023 | 79.03% | Stephens & Co. | → $555 | Reiterates | Overweight → Overweight | |||
07/13/2023 | 85.48% | UBS | $610 → $575 | Maintains | Buy | |||
07/12/2023 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
07/07/2023 | 72.58% | JP Morgan | $572 → $535 | Maintains | Overweight | |||
06/20/2023 | 80.65% | Truist Securities | $580 → $560 | Maintains | Buy | |||
04/27/2023 | 84.19% | Morgan Stanley | $500 → $571 | Upgrade | Equal-Weight → Overweight | |||
04/24/2023 | 80.97% | Wells Fargo | $597 → $561 | Maintains | Overweight | |||
04/21/2023 | 77.42% | Loop Capital | $565 → $550 | Maintains | Buy | |||
04/21/2023 | 76.45% | Cantor Fitzgerald | → $547 | Initiates | → Overweight | |||
04/20/2023 | 81.94% | TD Cowen | $577 → $564 | Maintains | Outperform | |||
03/28/2023 | 84.52% | RBC Capital | $523 → $572 | Upgrade | Sector Perform → Outperform | |||
03/24/2023 | 87.1% | Truist Securities | $610 → $580 | Maintains | Buy | |||
03/21/2023 | -77.1% | Wells Fargo | $79 → $71 | Maintains | Equal-Weight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Elevance Health (ELV)?
El último precio objetivo de Elevance Health (NYSE:ELV) fue comunicado por Wells Fargo el agosto 15, 2025. La firma de analistas fijó un precio objetivo para $330.00 que espera ELV a rise dentro de 12 meses (un posible 6.45% upside). 48 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Elevance Health (ELV)?
La última calificación de analistas para Elevance Health (NYSE:ELV) fue proporcionada por Wells Fargo, y Elevance Health mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Elevance Health (ELV)?
La última revisión al alza de Elevance Health Inc se produjo en marzo 17, 2025, cuando Argus Research elevó su precio objetivo a $450. Argus Research anteriormente tenía a hold para Elevance Health Inc.
¿Cuándo fue la última revisión a la baja de Elevance Health (ELV)?
La última revisión a la baja de Elevance Health Inc se produjo en julio 21, 2025, cuando Argus Research cambió su precio objetivo de N/A a N/A para Elevance Health Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Elevance Health (ELV)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Elevance Health, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Elevance Health se registró el agosto 15, 2025, por lo que la próxima calificación estará disponible en torno al agosto 15, 2026.
¿Es correcta la calificación de los analistas sobre Elevance Health (ELV)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Elevance Health (ELV) fue un mantuvo con un precio objetivo de $400.00 a $330.00. El precio actual al que cotiza Elevance Health (ELV) es de $310.00, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.